Literature DB >> 17242172

Associations between promoter usage and alternative splicing of the glucocorticoid receptor gene.

Henk Russcher1, Virgil A S H Dalm, Frank H de Jong, Albert O Brinkmann, Leo J Hofland, Steven W J Lamberts, Jan W Koper.   

Abstract

The glucocorticoid receptor (GR) is widely expressed in various tissues throughout the human body. At least three different 3'-splice variants of the GR have been reported: GR-alpha, which is functionally active; GR-beta, which is a dominant negative inhibitor of GR-alpha function; and GR-P, which is thought to activate the function of GR-alpha. At least seven different variants for exon 1 exist, 1A-1F and 1H, each with its own promoter. In this study, we explored if tissue-specific splicing of the 3'-end variants of the GR is influenced by alternative promoter usage. cDNAs of different tissues and cell lines were used to investigate which part of transcripts carrying each of the three major variants for exons 1, 1A, 1B, or 1C, encodes for the splice variants GR-alpha, GR-beta, and GR-P. Our data demonstrate that the expression of GR-alpha is preferentially regulated by promoter 1C and that for the expression of GR-P promoter 1B is predominantly used. This indicates that regulation of GR splice variants could partly occur through selective use of the multiple promoters, and that this is another way to sensitize cells and tissues to the different activities of the GR isoforms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242172     DOI: 10.1677/jme.1.02117

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  20 in total

1.  Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance.

Authors:  Katherine L Gross; Robert H Oakley; Alyson B Scoltock; Christine M Jewell; John A Cidlowski
Journal:  Mol Endocrinol       Date:  2011-04-28

Review 2.  The determinants of alternative RNA splicing in human cells.

Authors:  Tatsiana V Ramanouskaya; Vasily V Grinev
Journal:  Mol Genet Genomics       Date:  2017-07-13       Impact factor: 3.291

3.  Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.

Authors:  Lindsay K Smith; John A Cidlowski
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

4.  Glucocorticoid receptor auto-upregulation and its relation with glucocorticoid sensitivity in idiopathic nephrotic syndrome.

Authors:  Peisong Chen; Tang Jiang; Juan Ouyang; Yingpeng Cui
Journal:  Int Urol Nephrol       Date:  2010-04-24       Impact factor: 2.370

Review 5.  The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease.

Authors:  A Sasha Tait; Cherie L Butts; Esther M Sternberg
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

6.  Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome.

Authors:  Grzegorz Zalewski; Anna Wasilewska; Walentyna Zoch-Zwierz; Lech Chyczewski
Journal:  Pediatr Nephrol       Date:  2008-03-15       Impact factor: 3.714

7.  Alternative splicing in exon 9 of glucocorticoid receptor pre-mRNA is regulated by SRp40.

Authors:  Xue-Bo Yan; Chen-Hong Tang; Yan Huang; Hui Fang; Zhi-Qiang Yu; Li-Min Wu; Rong-Yu Liu
Journal:  Mol Biol Rep       Date:  2009-04-03       Impact factor: 2.316

8.  Progesterone receptor (PR) variants exist in breast cancer cells characterised as PR negative.

Authors:  David M W Cork; Thomas W J Lennard; Alison J Tyson-Capper
Journal:  Tumour Biol       Date:  2012-09-07

Review 9.  Molecular mechanisms regulating glucocorticoid sensitivity and resistance.

Authors:  Katherine L Gross; Nick Z Lu; John A Cidlowski
Journal:  Mol Cell Endocrinol       Date:  2008-10-19       Impact factor: 4.102

10.  Effect of glucocorticoid receptor gene polymorphisms on asthma phenotypes.

Authors:  Michał Panek; Tadeusz Pietras; Artur Fabijan; Maciej Miłanowski; Lukasz Wieteska; Paweł Górski; Piotr Kuna; Janusz Szemraj
Journal:  Exp Ther Med       Date:  2012-11-13       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.